Intelligence / Healthtech / New Clinical Trials / YGION Biomedical GmbH
Clinicaltrial registered12 Nov 2026
YGION Biomedical GmbH
12 Nov 2026: Trial registered · First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 12 Nov 2026
- Title
- First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma
- Conditions
- Glioblastoma
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Austria
- Country
- Austria
- Reference
- NCT07930338
- Location
- Austria
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at YGION Biomedical GmbH
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Austria
New Clinical Trials
16 NovPolymedics Innovations Inc.trial registered · Influence of SUPRA SDRM on the Healing of Chronic WoundsClinical12 NovCroma-Pharma GmbHtrial registered · Revitalis - Midface (Cheek Area)Clinical9 NovAqua Therapeutics, Inc.trial registered · Clinical Study on the Safety and the Performance of an Endometrial Ablation System in Women With Abnormal Uterine Bleeding (AUB) and Previous Cesarean DeliveryClinical4 NovBoehringer Ingelheimtrial registered · A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Clinical28 OctMED-EL Elektromedizinische Geräte GmbHtrial registered · Mi2000 TICI Follow-upClinical28 OctNuvascular Inctrial registered · The NUVASCULAR HARBOR Occlusion Device EU StudyClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.